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A B S T R A C T
Anthelmintic resistance is a global problem that threatens sustainable control of the equine gastrointestinal
cyathostomins (Phylum Nematoda; Superfamily Strongyloidea). Of the three novel anthelmintic classes that
have reached the veterinary market in the last decade, none are currently licenced in horses, hence current
control regimens focus on prolonging the useful lifespan of licenced anthelmintics. This approach would be
facilitated by knowledge of the resistance mechanisms to the most widely used anthelmintics, the macrocyclic
lactones (ML). There are no data regarding resistance mechanisms to MLs in cyathostomins, although in other
parasitic nematodes, the ABC transporters, P-glycoproteins (P-gps), have been implicated in playing an im-
portant role. Here, we tested the hypothesis that P-gps are, at least in part, responsible for reduced sensitivity to
the ML ivermectin (IVM) in cyathostomins; ﬁrst, by measuring transcript levels of pgp-9 in IVM resistant versus
IVM sensitive third stage larvae (L3) pre-and post-IVM exposure in vitro. We then tested the eﬀect of a range of P-
gp inhibitors on the eﬀect of IVM against the same populations of L3 using the in vitro larval development test
(LDT) and larval migration inhibition test (LMIT). We demonstrated that, not only was pgp-9 transcription
signiﬁcantly increased in IVM resistant compared to IVM sensitive L3 after anthelmintic exposure (p < 0.001),
but inhibition of P-gp activity signiﬁcantly increased sensitivity of the larvae to IVM in vitro, an eﬀect only
observed in the IVM resistant larvae in the LMIT. These data strongly implicate a role for P-gps in IVM resistance
in cyathostomins. Importantly, this raises the possibility that P-gp inhibitor-IVM combination treatments might
be used in vivo to increase the eﬀectiveness of IVM against cyathostomins in Equidae.
1. Introduction
The most prevalent and pathogenic gastrointestinal nematodes (GI)
of Equidae in developed countries are the cyathostomins (Love et al.,
1999; Kaplan and Vidyashankar, 2012); a group of clade V nematodes
belonging to the superfamily Strongyloidea (Lichtenfels et al., 1998).
Their pathogenic eﬀect ranges from non-speciﬁc weight loss to colic
and larval cyathostominosis. The latter is a potentially fatal colitis
caused by mass emergence of larvae from the large intestinal wall
(Uhlinger, 1991; Murphy and Love, 1997; Lyons et al., 2000; Peregrine
et al., 2006). Of the three major classes of anthelmintics available to
treat cyathostomin infections, there is already widespread resistance to
the benzimadazoles and pyrantel (Nielsen et al., 2014; Peregrine et al.,
2014). As a consequence, the macrocyclic lactone (ML) anthelmintics,
ivermectin (IVM) and moxidectin (MOX) have been the mainstay of
treatment and control programmes in recent years. However, there is
now increasing evidence that cyathostomins are developing resistance
to MLs (Trawford et al., 2005; Molento et al., 2008; Milillo et al., 2009;
Traversa et al., 2009; Trawford and Burden, 2009; Nareaho et al., 2011;
Canever et al., 2013; Relf et al., 2014; Tzelos et al., 2017), primarily
evidenced by reduced strongyle egg reappearance periods (ERPs) after
treatment. Crucially, none of the novel anthelmintics which have
reached the animal health market in the last decade, for example,
monepantel, derquantel and emodepside, are licenced for use in equids,
nor are they likely to be in the near future. For these reasons, the focus
of current control regimens is on prolonging the useful life span of the
http://dx.doi.org/10.1016/j.ijpddr.2017.10.006
Received 19 July 2017; Received in revised form 17 October 2017; Accepted 23 October 2017
☆ Nucleotide sequence data reported in this paper are available in the GenBank™, EMBL and DDBJ databases under the accession numbers: MF498738-MF498747 for sequences Clone
A1-5, B1-5 respectively.
∗ Corresponding author.
1 Present address: Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge, CB3 0ES.
E-mail addresses: peachey14@hotmail.com, peach14@liv.ac.uk (L.E. Peachey).
IJP: Drugs and Drug Resistance 7 (2017) 388–398
Available online 25 October 2017
2211-3207/ © 2017 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/BY/4.0/).
T
currently eﬀective anthelmintics, in particular ML products (Matthews,
2014). This would be greatly facilitated by an understanding of re-
sistance mechanisms to MLs in cyathostomins, of which little is cur-
rently known.
There has been extensive investigation into mechanisms underlying
ML resistance in other parasitic nematode species; however, a mono-
genic mechanism, for example a target site mutation in a glutamate
gated chloride channel, has yet to be identiﬁed (El-Abdellati et al.,
2011; Williamson et al., 2011). One group of genes, those that encode
ATP-binding cassette (ABC) transporters, have been strongly implicated
in ML resistance in several nematode species (Xu et al., 1998; Ardelli
and Prichard, 2007; Lifschitz et al., 2010a, 2010b; Bourguinat et al.,
2011; Dicker et al., 2011; Geary et al., 2011; Williamson et al., 2011;
Ardelli, 2013; Janssen et al., 2013a, 2013b; AlGusbi et al., 2014; Tyden
et al., 2014; Raza et al., 2015). ABC transporters are large transmem-
brane proteins found in cells throughout Archaea, Eubacteria and Eu-
karya, and amongst multiple functions, they are responsible for ATP-
dependant eﬄux of xenobiotic compounds from cells, and so play an
important role in protection against toxic environmental compounds
(Dassa, 2003). In mammals, through their expression at epithelial
barriers such as the blood brain barrier, hepato- and enterocytes, ABC
transporters are important in the pharmacokinetic dynamics of hydro-
phobic drugs such as MLs (Schinkel et al., 1994; Laﬀont et al., 2002;
Ballent et al., 2006; Kiki-Mvouaka et al., 2010).
Numerous ABC transporters have been shown to be expressed in
nematodes; for example, Caenorhabditis elegans has 14 P-glycoprotein
(P-gp) and 8 membrane resistance protein (MRP) genes (Ardelli, 2013).
In H. contortus, P-gp expression has been shown to predominate in the
gastrointestinal (GI) tract, particularly the pharynx and anterior intes-
tine (Smith and Prichard, 2002), leading to the hypothesis that P-gps
may play an important role in nematode drug metabolism. In support of
this, it was demonstrated that MLs are good substrates for ABC trans-
porters (Lespine et al., 2006, 2007, 2009; Dupuy et al., 2006, 2010;
Kiki-Mvouaka et al., 2010; David et al., 2016), and studies in C. elegans
using strains with loss-of-function mutations in ABC transporters have
shown that various ABC-transporter knockout combinations confer in-
creased sensitivity to MLs (Ardelli and Prichard, 2013; Janssen et al.,
2013b). There is growing evidence that ABC transporters, in particular
P-gps, are involved in nematode ML resistance. A reduction in P-gp
gene heterozygosity after IVM exposure in O. volvulus and H. contortus
indicated that certain P-gp genotypes may confer an advantage for
nematodes in the presence of IVM (Ardelli et al., 2005; Ardelli and
Prichard, 2007; Blackhall et al., 2008). Up-regulation in P-gp and MRP
mRNA was observed in ML resistant strains of C. elegans (MRP-1, MRP-
6, pgp-1 and pgp-2), H. contortus (pgp-2, pgp-9) and T. circumcincta (pgp-
9) (James and Davey, 2009; Dicker et al., 2011; Williamson et al., 2011;
Ardelli and Prichard, 2013), indicating that increased drug eﬄux via
these channels may play a role in resistance. In Cooperia oncophora,
Ostertagia ostertagi, C. elegans, H. contortus and T. circumcincta, it was
shown that addition of P-gp inhibitors to ML resistant nematodes in
vitro has the eﬀect of increasing ML sensitivity (Bartley et al., 2009;
Ardelli and Prichard, 2013; Demeler et al., 2013; AlGusbi et al., 2014;
Raza et al., 2015; Ménez et al., 2016). This eﬀect has also been re-
produced in vivo where a combination of IVM and/or moxidectin with
the P-gp inhibitor loperamide increased the eﬀectiveness of the an-
thelmintics in ML resistant nematode populations in sheep and cattle
(Lifschitz et al., 2010a, 2010b). This eﬀect is thought to be due, in part,
to increased bioavailability of IVM due to modulation of host P-gps, but
there may be a direct eﬀect of P-gp inhibitors on parasite drug trans-
port.
There are little data regarding ABC transporters in cyathostomins;
characterisation of these molecules in this group of parasites is com-
plicated by the number of species that exist and that they virtually al-
ways occur as co-infections with multiple species (Ogbourne, 1976;
Reinemeyer et al., 1984; Love and Duncan, 1992; Bucknell et al., 1995;
Gawor, 1995; Traversa et al., 2010). One publication reported partial
nucleotide sequences of two P-gp nucleotide-binding domains in several
common species of cyathostomins (Drogemuller et al., 2004). Analysis
of these sequences suggested the possibility of at least two P-gp genes in
the study samples. Subsequently, the full DNA sequence of the pgp-9
gene in Cylicocyclus elongatus was published and in this study, IVM was
shown to inhibit pgp-9 mediated protection of yeast cells against the
fungicide ketoconazole (Kaschny et al., 2015). In the current study, the
role of pgp-9 in cyathostomin resistance to IVM was investigated. A real-
time PCR assay was used to compare pgp-9 transcript levels between
cyathostomins from: 1) a population of equids with a long history of ML
use and reduced strongyle ERP and 2) an equid population that had
never been exposed to anthelmintics. The eﬀect of a range of P-gp in-
hibitors on IVM eﬃcacy was also compared in vitro in these nematode
populations using the larval development test (LDT) and the larval
migration inhibition test (LMIT) (Demeler et al., 2010b; McArthur
et al., 2015).
2. Materials and methods
2.1. Parasite populations
Cyathostomins were sourced from two populations of diﬀering ML
sensitivity, Population 1 (Pop 1, IVM-resistant), comprised ‘resistant’
cyathostomins, from donkeys at the Donkey Sanctuary, (Sidmouth,
Devon UK) where there was a history of resistance to MLs (Trawford
et al., 2005; Trawford and Burden, 2009). ‘Resistant’ cyathostomins
were deﬁned by their response to treatment in vivo, and were obtained
from animals with a faecal egg count (FEC) of ≥500 eggs per gram
(epg) within ﬁve weeks of administration of IVM or MOX. Population 2
(Pop 2, IVM-naive), were deemed to be ML ‘sensitive’ cyathostomins,
and were derived from Konik horses used for conservation purposes by
the National Trust (Wicken Fen, East Anglia, UK). This was a closed
herd that had not previously received anthelmintics, and additionally
IVM median eﬀective concentration (EC-50) values from this cyathos-
tomin population have previously been shown to be signiﬁcantly lower
than those from the Population 1 (McArthur et al., 2015). It was not
possible to perform a faecal egg count reduction test (FECRT) to con-
ﬁrm sensitivity in Pop 2 as anthelmintic treatment was prohibited. An
archive of morphologically identiﬁed adult cyathostomins collected
from horses and donkeys post-mortem and stored in ethanol at -20 °C,
was used for ampliﬁcation of pgp-9 and design of a real-time poly-
merase chain reaction (PCR) (Hodgkinson et al., 2008).
2.1.1. Strongyle egg extraction
Fresh faeces were placed in air tight polythene bags (Fisher, UK) and
strongyle eggs extracted within 1 h of collection or, if not, stored
anaerobically in tap water (H2O) at room temperature for no longer
than one week (Coles et al., 1992). Extracted eggs were decanted into
50 ml containers (VWR, UK) and concentration ascertained by counting
the number of eggs in 5 × 10 μl at 100 × magniﬁcation (Leica, Stereo).
Mean counts were multiplied by 100 to give number of eggs/1 ml. Egg
suspensions were used in the LDT immediately after extraction. A
subset of eggs from each sample was cultured to third stage larvae (L3)
to rule out presence of Strongylus spp., and hence ensure that only cy-
athostomin L3 were used in in vitro tests (Thienpont et al., 1986).
2.1.2. Larval culture
Larval culture was performed as described by McArthur et al. (2015)
to harvest L3. The concentration of L3 was ascertained by counting the
number of L3 in 5 × 10 μl at 100 × magniﬁcation and taking an
average of each count × 100 to give the number of L3/1 ml. Samples
were examined for the presence of Strongylus spp. as above, and only
samples where no large strongyles were detected were used. Samples
were stored at 4 °C and used within eight weeks.
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2.2. Design of real time PCR for measurement of cyathostomin pgp-9
transcription
2.2.1. Identiﬁcation of pgp-9 DNA sequence from adult cyathostomins
RNA was extracted from groups of 10 adult worms from a mixed adult
cyathostomin sample taken from a donkey (W) at the Donkey Sanctuary
(DSW), using the QIAGENRNeasy Mini kit using a bead beater for 2 min at
4800 rpm. cDNA synthesis was performed using the QIAGEN Quantitect
Reverse Transcriptase kit and cDNA stored at -20 °C. Partial pgp-9 trans-
lated amino acid sequence from T. circumcincta (AN:CBX21126.1) and H.
contortus (AN:AFX93750.1), and full pgp-9 translated amino acid sequence
from C. elegans (AN:CAB03973) and C. elongatus (AN: KJ701410) were
aligned using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/)
to identify conserved regions in the nematode pgp-9 gene; speciﬁcity of
this region was conﬁrmed by BLAST analysis (http://blast.ncbi.nlm.nih.
gov/Blast.cgi?PAGE=Proteins). NCBI primer design (http://www.ncbi.
nlm.nih.gov/tools/primer-blast/) with the C. elongatus nucleotide se-
quence (A.N. KJ701410.1) was used to identify a forward primer located
in this conserved region, and a reverse primer located in the highly con-
served ﬁrst nucleotide binding domain (Kaschny et al., 2015). Next, de-
generate primers were designed by alignment with H. contortus (A.N.
JX430937.1) nucleotide sequence, thus maximising the likelihood that the
primers would amplify pgp-9 from multiple cyathostomin species. The
primers were as follows: forward, PGP9F 5′-CKGCMACRATACAGGCAA-
TR-3′ and reverse PGP9R 5′-GTCCTCACGTCCMGAMARTTG-3. PCR was
performed using QIAGEN Taq PCR Master Mix Kit. To each reaction, 25 μl
Master Mix, 2.5 μl forward and reverse primer (ﬁnal concentration
0.5 μM), 18 μl DNase free water, and 2 μl template cDNA were added, to
give a total volume of 50 μl. The PCR reaction was run on the Biometra T3
Thermocycler under the following conditions: 3 min at 94 °C, followed by
34 cycles of 1 min denaturation at 94 °C, 1 min at 52 °C and 1 min ex-
tension at 72 °C, and a ﬁnal extension phase of 10 min at 72 °C. PCR
products were subjected to electrophoresis on 1% agarose gels at 100 V for
30 min and the products stained for UV visualisation using ‘SYBR safe’
stain (Life Technologies, UK), alongside a 1000 bp ladder (Invitrogen, UK).
PCR products were puriﬁed using the QIAGEN QIAquick Gel extraction
kit, quantiﬁed using the Invitrogen Qubit Assay, and cloned using the
pGEM-T Easy Vector System (Promega). Plasmid DNA was puriﬁed from
the cells using the Promega Wizard Plus SV Minipreps DNA Puriﬁcation
System, as per manufacturer's instructions. DNA was quantiﬁed using the
Qubit assay (Invitrogen) and 100 ng/μl from 10 separate colonies se-
quenced using a commercial service (Source Biosciences, UK). Resultant
sequences (designated DSW A1-5 and B1-5) were entered into NCBI nu-
cleotide BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=
BlastSearch). Alignments between cDNA and amino acid sequences of
all clones and C. elongatus pgp-9 (A.N. KJ701410.1) were created using
Clustal Omega, and percentage identity calculated. A maximum likelihood
tree with 500 bootstraps using a kimura 2-parameter model, was con-
structed comparing DW1 A1-5 and B1-5, C. elongatus pgp-9 (A.N.
KJ701410.1), H. contortus pgp-9 (A.N. JX430937.1), T. circumcincta pgp-9
(A.N. FR691848.1), C. elegans pgp-9 (C47A10.1 wormbase i.d.) and Cae-
norhabditis briggsae pgp-9 (XM_002638567.1) created using MEGA version
6.06 software.
2.2.2. Design and optimisation of a real-time PCR assay for quantiﬁcation
of cyathostomin pgp-9 cDNA
A SYBR® green (Life Technologies) real time quantitative PCR assay
was designed to determine pgp-9 transcript levels in cDNA samples. A
single housekeeping gene, the 18S rRNA gene, was used to allow for
multi-species referencing. The 18S assay was designed using a con-
sensus sequence of 99 bp produced from the alignment of the 18S rRNA
from six cyathostomin species and other organisms as follows: C. la-
biatum (A.N. AJ223727); C. ashworthi (A.N. AJ223346); C. nassatus,
(A.N. AJ223348); C. elegans, (A.N. X03680); Ascaris suum, (A.N.
U94367.1); Toxoplasma gondii, (A.N. L37415); Schizosaccharomyces
pombe, (A.N. AY251644); Diroﬁlaria immitis, (A.N. AF036638); Xenopus
laevis, (A.N. X02995); Drosophila melanogaster, (A.N. M21017);
Strongyloides stercoralis, (A.N. M84229); and Enoplus brevis, (A.N.
U88336). Primers were as follows; 18SRTf 5′ GATTGATTCT
GTCAGCGCTATA 3′ and 18SRTr 5′ TAATGAGCCGTTCGCAGT 3’. A
standard consensus synthetic 99 bp 18S template corresponding to the
cyathostomin species above, was manufactured by Sigma-Aldrich, UK.
For pgp-9, primers were designed using Primer 3 version 4.0.0 (http://
primer3.ut.ee/) based on the sequence data from DSW A1. The primers
with the best thermokinetic parameters were chosen and aligned with
all 10 sequenced pgp-9 sequences and C. elongatus pgp-9 (A.N.
KJ701410.1), degenerate primers were designed to maximise ampliﬁ-
cation of pgp-9 from multiple cyathostomin species. The degenerate
primers for pgp-9 were PGP9RTF 5′ AYATTGGGCTYGGTCTTGCT 3′ and
PGP9RTR 5′ ACCGTTCCYCCTTTCATCGT 3’. The 112 bp sequence in-
cluding the two primers was synthesised by Sigma-Aldrich, UK, for use
as a Pgp-9 standard with the most commonly occurring base in-
corporated at each of the 12 sites of nucleotide variation. A 10-fold
dilution series of the 18S and pgp-9 standard oligonucleotides was made
in 100 μg/ml yeast tRNA (Invitrogen, UK). Final theoretical copy
numbers for each dilution were 5 × 10−1, 5 × 100, 5 × 101, 5 × 102,
5 × 103, 5 × 104, 5 × 105, 5 × 106, 5 × 107, 5 × 108. Primers
18SRTf, 18SRTr, PGP9RTF and PGP9RTR were diluted to 100 μM. A
master mix was made up with 10 μl 2 × SensiMix (dT) (Bioline, UK),
7 μl DNase/RNase free dH2O (Sigma-Aldrich, UK), 1 μl 4 μM forward
and reverse primer (either for 18S or pgp-9) per sample. To each well of
a 96-well plate, 19 μl mastermix were added, followed by 1 μl of each
standard concentration. Duplicates were run for each standard con-
centration and a non-template control (dH2O) was included. The plate
was run on a DNA Engine Opticon 2 Continuous Fluorescence detector
(BioRad), with the reaction conditions: 95° C for 10 min, followed by 35
cycles of 95 °C for 15 s, 53 °C for 30 s and 72 °C for 15 s. The standard
curve was repeated with the addition of serial dilutions of cDNA from
DSW. Analysis of cDNA concentration, showed that pgp-9 detection was
best at a concentration of 4 ng/μl. The optimised real time PCR was also
run on cDNA from Cylicocyclus nassatus, Cyathostomum pateratum and
Cyathostomum catinatum parasites to ensure that the assay could detect
pgp-9 from a range of cyathostomin species (data not presented).
2.3. Evaluation of pgp-9 transcript levels after ivermectin exposure of third
stage larvae from mixed species cyathostomin populations of diﬀering
ivermectin sensitivity
A total of∼800,000 and∼1.1 million L3 were obtained from faeces
of 10 animals for each population. L3 were pooled for each population
and suspended in 450 ml distilled water (dH2O) (Sigma-Aldrich). These
were mixed and divided into three aliquots of 50 ml (negative controls),
and 6 aliquots of 48.5 ml (test samples) and placed into 50 ml cen-
trifuge tubes. L3 in each aliquot were ex-sheathed with 7% sodium
hypochorite (Miltons) for 3.5 min then washed three times by cen-
trifugation at 200 × g for 2 min. To three of the 48.5 ml test samples,
1.5 ml DMSO (Sigma-Aldrich, UK) were added to serve as a control for
the drug solvent. To the remaining samples, 1.5 ml 2.28 μM IVM
(Sigma-Aldrich, UK) in DMSO were added, giving a ﬁnal IVM con-
centration of 0.0684 μM. This concentration was chosen as a ‘sub-lethal’
dose (i.e. where percentage larval migration began to decrease, but the
majority of the L3 were still alive and presumably still capable of
transcribing RNA), based on data from pilot experiments (data not
shown). Aliquots were incubated with L3 for 2 h at 26 °C then cen-
trifuged for 2 min at 200 × g, the supernatant removed and L3 re-
suspended in 20 ml dH2O. This was repeated three times. Finally, L3
were transferred to a micro-centrifuge tube and centrifuged for 5 min at
11,000 × g. The remaining supernatant was removed and L3 were air
dried, re-suspended in 100% ethanol (Sigma-Aldrich, UK) and stored at
-20 °C. RNA extraction and cDNA synthesis were carried out on each L3
sample as described above. In the cDNA synthesis step, reverse tran-
scriptase-free negative controls were included for each aliquot. The
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cDNA concentration in each sample was quantiﬁed using the Picogreen
DNA quantiﬁcation kit (Promega). The cDNA concentration in each
aliquot was standardised to 2 ng/μl using RNase/DNase-free water
(Sigma-Aldrich, UK). Real time PCR for 18S and pgp-9 was performed
alongside standard curves for all samples according to the method
above except, to maintain cDNA concentrations close to the optimum
described above, 2 μl cDNA were added to each reaction to give a total
of 4 ng reverse-transcribed RNA per reaction. Technical duplicates were
included for each sample, as well as reverse transcriptase-free negative
controls and non-template controls. For each incubation (i.e. dH2O, 3%
DMSO or 0.15 μg/ml IVM), there were two technical (within assay)
repeats in addition to the three biological repeats described above.
2.4. Analysis of real time PCR data
Raw data from the real-time PCR was evaluated using Opticon
Monitor 3 version 3.1.32.0 software. Standard graph correlations were
examined and melting curves observed for each sample; those that did
not have a single peak at the expected temperature were excluded from
further analysis. Raw data from the qPCR reactions were entered into a
Microsoft Excel spreadsheet. The percentage genomic contamination in
each sample was calculated from the reverse transcriptase negative
control for the raw 18S data; this was used to correct the raw data for
18S and pgp-9 so that genomic DNA was not counted. The average copy
number between each technical repeat was taken for each sample for
18S and pgp-9, and the relative transcript level of pgp-9 gene compared
to the 18S gene, calculated for each biological repeat. These data were
analysed with two-way analysis of variance (ANOVA), to compare pgp-9
transcription between treatments and equid populations, using R sta-
tistical software (R Core Team, 2014).
2.5. Pharmaceutical preparations for use in the larval development test and
larval migration inhibition test
IVM (Sigma-Aldrich, UK) was dissolved in DMSO (Sigma-Aldrich,
UK) to give stock solutions of 5000 nM for the LDT and 3420 μM for the
LMIT. These were serially diluted in DMSO before use to give ﬁnal
concentrations in the two tests: 25, 13, 6.3, 3.1, 1.6, 0.78, 0.39, 0.20,
0.10, 0.05 nM in the LDT and 102.6, 51.3, 20.5, 10.3, 2.05, 0.684,
0.171, 0.0684, 0.0342, 0.0171 μM in the LMIT. The concentration of
the three P-gp inhibitors tested, pluronic 85 (P85), ketoconazole (K)
and ivermectin aglycone (IVM-AG), were optimised for use in the LDT
and LMIT, so that concentrations were optimal for P-gp inhibitory ac-
tivity, without having an anthelmintic eﬀect. The concentrations of P85
and ketoconazole that lead to maximum P-gp inhibition had been re-
ported previously as 22 μM and 10 μM, respectively (Bartley et al.,
2009). Adaptations of the LMIT and LDT were performed with dose
titrations of all three P-gp inhibitors. There was no eﬀect on larval
migration or development at the published optimal concentrations for
P85 and K, hence they were used in further tests. The concentration of
IVM-AG that leads to maximum P-gp inhibition has not been previously
established, thus an additional test was run, where increasing con-
centrations of IVM-AG were compared with increasing concentrations
of IVM-AG plus 1 μM IVM. This was done to determine the con-
centration at which the addition of IVM-AG optimally improved in-
hibition of larval migration or development compared to IVM alone.
The optimal concentration was found to be 60 nM for the LMIT (data
not shown). In the LDT, IVM-AG showed anthelmintic activity at con-
centrations greater than 10 nM so it was necessary to use a con-
centration of 8 nM, even though this may not have been optimal for P-
gp inhibition. K (Sigma-Aldrich, UK) was used at 10 μM in all tests with
the LDT and LMIT. For the LDT, a stock solution of 2000 μM in DMSO
was used and added in a 0.5:100 ratio to the test, and for the LMIT a
1000 μM in DMSO was used and added in a 1:100 ratio at each stage of
the test. Pluronic 85 (P85) (BASF, USA) was used at 22 μM in the LDT
and LMIT. For the LDT, a stock solution of 4400 μM in dH2O (Sigma-
Aldrich, UK) was added in a 0.5:100 ratio. For the LMIT, a stock so-
lution of 2200 μM in dH2O was used and added in a 1:100 ratio at each
stage of the test. IVM-AG (synthesised at Toxalim, INRA) was used at
8 nM in the LDT and, for this, a stock solution of 1600 nM was used and
added in a 0.5:100 ratio. In the LMIT, IVM-AG was used at a con-
centration of 60 nM and, for this, a stock solution of 6000 nM was used,
which was added in a 1:100 ratio.
2.6. The larval development test with pluronic 85, ketoconazole and
ivermectin aglycone
The LDT with IVM was performed on samples from Pop 1 and Pop 2,
as previously described (Demeler et al., 2010b), using the working
concentrations of IVM described above in duplicate. Duplicate negative
controls of dH2O were also included. The LDT was repeated with the
addition of 10 μM ketoconazole, 22 μM P85 and 8 nM IVM-AG in all
wells, including the negative control, for two samples from each po-
pulation. The working concentrations of IVM were adjusted to keep the
DMSO concentration constant at 0.5%.
2.7. The larval migration inhibition test with pluronic 85, ketoconazole and
ivermectin aglycone
The LMIT with IVM was performed on samples from Pop 1 and Pop
2, as previously described (McArthur et al., 2015), using the working
concentrations of IVM described above. The test was repeated in four
parasite samples from each population. For each sample, the test was
then repeated with the addition of 10 μM ketoconazole, 22 μM P85 or
60 nM IVM-AG in all wells, including the negative control. The working
concentrations of IVM were adjusted to keep the DMSO concentration
constant at 3%.
2.8. Analysis of dose response data from the larval development test and
larval migration inhibition tests
The percentage of larvae which did not develop or migrate in ne-
gative controls in each test was deﬁned as the ‘natural mortality’. The
raw data were subsequently corrected for ‘natural mortality’ at each
concentration and the percentage egg hatch or larval migration re-
calculated. The corrected data were used to calculate logistic sigmoid
dose response curves in Graphpad Prism 7. For each test, four para-
meters were deﬁned in a model according to the equation:
y = bottom+(top-bottom)/1 + 10(logEC−50-x)∗hillslope
where x = log10 concentration, y = percentage hatch/migration,
bottom = the y value at the bottom plateau, top = the y value at the
top plateau, and hillslope = the gradient of the curve. This enabled
calculation of the median eﬀective concentration (EC-50) for compar-
ison between tests. Goodness of ﬁt for each model was evaluated by the
R2 value and the conﬁdence intervals. Where appropriate parameters
(top and bottom) were constrained to allow statistical comparison be-
tween repeats using the sum of squares F test, the p value was corrected
for multiple comparisons between repeats, with p < 0.008 indicating a
signiﬁcant diﬀerence between models.
The ratio between the EC-50 for IVM alone and IVM plus P-gp in-
hibitor was calculated to give a ‘synergy ratio’ (SR) representing the
eﬀect of the inhibitor on IVM eﬃcacy. In addition, the ratio of the EC-
50s between the two populations was calculated for the LMIT and LDT
to give a resistance ratio representing the diﬀerence in IVM sensitivity
between the two populations.
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3. Results
3.1. Identiﬁcation of cyathostomin pgp-9 sequences
PCR for pgp-9 using primers designed from a consensus sequence of
C. elongatus and H. contortus was positive in DSW with an amplicon of
the expected size, 1100bp, observed. The nucleotide sequence of clone
A1 was found to have 92% identity to the pgp-9 genes previously
identiﬁed in C. elongatus across 100% of the amplicon. BLASTn analysis
showed 77% and 74% identity to H. contortus and T. circumcincta pgp-9,
respectively, and lower levels of identity to other nematode species
(Table 1). A nucleotide sequence alignment of all 10 sequences (A1-5
and B1-5) from the DSW Pgp-9 PCR product showed the range of
identity to be between 91.1% (between C. elongatus and sequence B4
and A4) and 99.8% (between sequence B2 and B3). The maximum
likelihood phylogenetic tree for nucleotide sequences (Fig. 1) indicated
with a 100% bootstrap probability that the sequences from DSW are
more closely related to C. elongatus than to sequences from other ne-
matode species. For the 10 sequences from DSW, there was an 80%
bootstrap probability that these constitute a single cluster forming a
sister group to C. elongatus pgp-9. Within this cluster, there were few
diﬀerences between sequences and it was unlikely that these re-
presented phylogenetically distinct sequences from diﬀerent species, as
reﬂected by the lower bootstrap values. The alignment of deduced
amino acid coding sequences for the 10 DSW sequences and the cor-
responding gene region of C. elongatus, is shown in Supplementary
Fig. 1. The sequence revealed the typical domain arrangement of one
half of the P-gp gene with an ABC transporter transmembrane domain
containing transmembrane helices followed by the ﬁrst part of the ﬁrst
nucleotide binding domain containing the highly-conserved Walker A/
P loop (CDD accession number cd03249).
3.2. Pgp-9 mRNA expression in L3 from two mixed species populations of
cyathostomins with diﬀering ivermectin sensitivity
Copy numbers of pgp-9 transcript relative to the housekeeping gene
18S in L3 in Pop 1 (IVM-resistant) and Pop 2 (IVM-sensitive) after in-
cubation with dH2O, 3% DMSO or 0.0684 μM IVM for 2 h are
Table 1
Results of NCBI blastn search of the sequence of DSW A1 pgp-9 PCR product.
Nucleotide sequence hit Accession Max Score Total Score Query cover E-value Identity
Cyclocylcus elongatus P-glyocprotein (pgp9) mRNA, complete cds KJ701410.1 1418 1418 100% 0.0 92%
Haemonchus contortus isolate Weybridge P-glycoprotein 9a mRNA partial cds JX430937.1 778 778 99% 0.0 77%
Teladorsagia circumcincta partial mRNA for p-glycoprotein 9, nucleotide binding domain 1 (pgp-9
gene)
FR691848.1 677 677 99% 0.0 74%
Necator americanus ABC transporter transmembrane region mRNA XM_013451424.1 333 586 79% 3e-88 80%
Caenorhabditis briggsae C CBR-PGP-9 protein (Cbr-pgp-9) mRNA complete cds XM_002638567.1 284 284 89% 1e-73 67%
Caenorhabditis remanei hypothetical protein (CRE_22140) mRNA, complete cds XM_003091578.1 269 269 92% 3e-69 66%
Caenorhabditis remanei hypothetical protein (CRE_27936) mRNA, complete cds XM_003090002.1 266 266 96% 3e-68 66%
Cyclostephanus goldi genome assembly C_goldi_Cheshire, scaﬀold CGOC_contig0005008 LL376643.1 262 392 41% 4e-67 74%
Cyclostephanus goldi genome assembly C_goldi_Cheshire, scaﬀold CGOC_contig0000757 LL362081.1 255 1051 88% 6e-65 75%
Cyclostephanus goldi genome assembly C_goldi_Cheshire, scaﬀold CGOC_contig0002917 LL371363.1 230 580 58% 2e-57 90%
Fig. 1. Maximum likelihood phylogenetic tree demonstrating the relationship between nucleotide sequences for DSW (A1-5 and B1-5) (highlighted red) and published pgp-9 sequences
from Cylicocylus elongatus pgp-9 (A.N. KJ701410.1), Haemonchus contortus pgp-9 (A.N. JX430937.1), Teladorsagia circumcincta pgp-9 (A.N. FR691848.1), Caenorhabditis elegans pgp-9
(C47A10.1 wormbase i.d.) and Caenorhabditis briggsae pgp-9 (XM_002638567.1). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
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represented in Fig. 2. After exposure to dH2O, there was no signiﬁcant
diﬀerence in pgp-9 transcript levels between Pop 1 and Pop 2
(p = 0.159). After exposure to DMSO, there were higher levels of pgp-9
transcript measured in Pop 1 compared to Pop 2 (p = 0.03). After
exposure to IVM there were higher levels of in pgp-9 transcript mea-
sured in Pop 1 compared to Pop 2 (p < 0.001). Within each popula-
tion, there was a signiﬁcant eﬀect of the diﬀerent treatments for Pop 1
(p = 0.005), but not for Pop 2 (p = 0.31). The fold-increase in pgp-9
mRNA level between the DMSO and IVM treatment in Pop 1 was 2.4.
3.3. Evaluating the eﬀect of P-glycoprotein inhibitors on ivermectin eﬃcacy
in the larval development test and larval migration inhibition test
Four-parameter dose response curves for each test (LMIT and LDT)
with each P-gp-inhibitor (K, IVM-AG and P85) are shown in Fig. 3. The EC-
50 values for the curves and the synergy ratio (SR) for IVM and IVM plus
P-gp inhibitor are represented in Table 2. For each group of tests, for ex-
ample, IVM alone and IVM + P-gp inhibitor in Pop 1 and 2 in the LDT/
LMIT, a signiﬁcant diﬀerence was found between the dose response
curves, using the sum of squares F test (p < 0.001 in both the LDT and
LMIT). From these results, in the LDT, P85 and K reduced EC-50s for IVM
in Pops 1 and 2, but to a lesser extent in Pop 1. In the LDT, IVM-AG had no
positive eﬀect on IVM eﬃcacy. In the LMIT, IVM-AG and K increased the
eﬀect of IVM in Pop 1, but had little eﬀect in Pop 2. In the LMIT, P85
increased the eﬀect of IVM at lower anthelmintic concentrations, but de-
creased the eﬀect at high concentrations; this had the eﬀect of raising the
bottom line of the four-parameter curve which meant that, although an
EC-50 value could be calculated for IVMwith P85 in the LMIT, it could not
be meaningfully compared with IVM alone using an SR. The mean re-
sistance ratio was 2.1 in the LDT and 9.0 in the LMIT.
4. Discussion
This study demonstrated that pgp-9 mRNA is upregulated in cy-
athostomins with phenotypic ML resistance, and that P-gp inhibitors
increase the eﬀect of IVM against these ML-resistant cyathostomins in a
LMIT. Taken together, this suggests a role for P-gps in IVM resistance in
these nematodes, and raises the possibility that P-gp inhibitors could be
used in equids, in combination with IVM, to increase eﬃcacy against
IVM-resistant cyathostomin populations, as has been done in sheep and
cattle (Lifschitz et al., 2010a, 2010b).
In this study, to design a real-time PCR assay to measure pgp-9
transcript in cyathostomins, pgp-9 cDNA was ampliﬁed from a mixed
species cyathostomin population. Preliminary analysis of the data in a
maximum likelihood phylogenetic model predicted with 100% cer-
tainty that there was a true diﬀerence between the sequences deﬁned in
this population and the previously characterised C. elongatus sequence
(A.N. KJ701410.1); this may reﬂect, either intra-speciﬁc variation or,
more likely, inter-speciﬁc variation due to the presence of multiple
diﬀerent cyathostomins species in the population studies here
(Cwiklinski, Matthews and Hodgkinson, unpublished). Additionally,
further analyses showed that the novel sequences reported here clus-
tered into two groups, raising the possibility that pgp-9 sequences from
two species of cyathostomin were ampliﬁed. Further work is required to
measure intra- and inter-speciﬁc variation of pgp-9 sequences across
cyathostomin species.
It is possible that selection for particular cyathostomins species with
upregulated P-gp transport pathways has occurred in the ‘resistant’
population here; a mechanism which diﬀers from one in which several
members of a mixed species population upregulate P-gp in response to
selection pressure. However, in support of the latter, data from the
‘resistant’ population shows a range of species present (Cyathostomum
catinatum, Cya. tetracantum, Cya. pateratum, Cylicostephanus long-
ibursatus, Cylicocyclus nassatus) (Cwiklinski, Matthews and Hodgkinson
unpublished). These species are concordant with those common species
that have been reported in populations across a range of geographic
regions and which have had varying exposure to macrocyclic lactone
anthelmintics (Bucknell et al., 1995; Gawor, 1995; Love and Duncan,
1992; Ogbourne, 1976; Reinemeyer et al., 1984; Traversa et al., 2010;
Eysker and Pandey, 1989; Getachew et al., 2010; Kharchenko et al.,
2009; Krecek et al., 1994).
Interestingly, it was noted that the DMSO solvent also induced a
modest increase in pgp-9 expression in the ‘resistant’ population, but not
in the ‘sensitive’ population. As P-gp drug eﬄux represents a non-spe-
ciﬁc mechanism designed to remove xenobiotics, it is possible that in a
population of parasites which are upregulating this mechanism, ex-
posure to chemicals such as DMSO may elicit a reactive upregulation of
P-gp; however, this hypothesis requires further investigation.
The higher levels of pgp-9 transcript detected in ML resistant versus
ML sensitive cyathostomins is in agreement with studies in T. cir-
cumcincta, H. contortus and Cooperia oncophora (Dicker et al., 2011;
Williamson et al., 2011; Areskog et al., 2013; Godoy et al., 2016).
Strong evidence for a role of pgp-9 in anthelmintic resistance in T. cir-
cumcincta has recently been reported in a genomic introgression map-
ping model of ﬁeld-derived multiple-anthelmintic resistant worms,
where a concurrent increase in copy number and transcript levels was
found for this gene (Choi et al., 2017). Additionally, Williamson et al.
(2011), measured transcript levels in H. contortus L3 cultured from
multi-drug resistant versus susceptible parasites that had been passaged
through goats, and found a 2.65-fold diﬀerence in pgp-9 transcript level,
similar to that observed here. Dicker et al. (2011) measured transcript
levels in all life cycle stages of T. circumcincta from a multidrug resistant
versus susceptible isolate, and reported a larger fold-diﬀerence (17.49)
in pgp-9. The reason for the larger diﬀerence in transcript level observed
in this study in comparison to the current and other ﬁndings, may be
that the data was generated using a homogenous multi-class resistant
strain, with ML FECR values of 60%, whereas here a reduced ERP was
used as a proxy for ML resistance. Additionally, the samples used here
were likely to encompass several cyathostomin species, which may
have introduced variation if the species had diﬀerent transcript levels.
Diﬀerent P-gps have been implicated in the transport of ivermectin
and ML resistance in other parasitic nematodes; for example, pgp-11 in
Cooperia oncophora and Parascaris equorum (De Graef et al., 2013;
Janssen et al., 2013a). De Graef et al. (2013) demonstrated increased
transcript levels of pgp-11 in adult worms isolated from calves that had
been treated with IVM or MOX. In addition, they were able to induce
increased transcript levels in L3 by exposing them to IVM in vitro in
resistant, but not susceptible isolates, similar to the ﬁndings here.
Studies in C. elegans have shown that diﬀerent combinations of ABC
transporter are associated with IVM and MOX sensitivity, indicating
that diﬀerent compounds are linked to speciﬁc transporters associated
with resistance (James and Davey, 2009; Ardelli and Prichard, 2013).
Fig. 2. Bar chart showing transcript levels of pgp-9 mRNA relative to the housekeeping
gene, 18S, in third stage larvae in Populations 1 ‘resistant’ and 2 ‘susceptible’, which had
been incubated with distilled water (H2O), dimethyl sulfoxide (DMSO) or ivermectin
(IVM) (*p =<0.05; **p=<0.001). Within each population, there was a signiﬁcant
eﬀect of the diﬀerent treatments for Pop 1 (p = 0.005), but not for Pop 2 (p = 0.31).
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Variations in P-gp subtype associated with resistance probably reﬂect a
diﬀerence in functionality of corresponding genes, such that the speciﬁc
P-gp involved in ML eﬄux may diﬀer among nematode species and ML
sub-type; however, it has been shown that increased susceptibility of C.
elegans carrying a loss-of-function mutation in the pgp-11 gene could be
rescued by expression of a Parascaris sp. pgp-11 transgene (Janssen
et al., 2015), hence further work is required to clarify these complex
interactions.
It was demonstrated here that the eﬀect of IVM in ‘resistant’ cy-
athostomins could be increased in vitro by its combination with certain
P-gp inhibitors. The LDT and LMIT were chosen as they are established
methods for evaluating IVM eﬃcacy in parasitic nematodes (Demeler
et al., 2010a, 2010b; McArthur et al., 2015). The RR between the two
cyathostomin populations reported here was lower for the LDT than the
LMIT, in agreement with previous studies in cyathostomins where the
LDT has shown poor correlation with in vivo phenotype (Tandon and
Kaplan, 2004; Lind et al., 2005). In H. contortus, the LDT is an estab-
lished technique for detecting diﬀerences in drug sensitivity (Dolinska
et al., 2013). These contrasting ﬁndings in cyathostomins may indicate
that they diﬀer with respect to the mode of action of IVM, and hence
potential mechanisms of resistance. Overall these data conﬁrm, as
previously reported by McArthur et al. (2015), that in cyathostomins
the LMIT is a useful in vitro tool for comparing the IVM sensitivity of L3
populations.
Fig. 3. Ivermectin (IVM) concentration response curves in Population 1 ‘resistant’ and 2 ‘susceptible’ (Pop 1, Pop 2) in the larval development test (LDT) and larval migration inhibition
test (LMIT), with and without the addition of the P-glycoprotein inhibitors ketoconazole (K), ivermectin aglycone (IVM-AG) and pluronic 85 (P85).
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Addition of P-gp inhibitors impacted the eﬀect of IVM in the LMIT
and LDT. This is consistent with studies in other parasitic nematodes
(Bartley et al., 2009; Ardelli and Prichard, 2013; Demeler et al., 2013;
AlGusbi et al., 2014; Raza et al., 2015). Overall, the eﬀect was depen-
dent on the isolate, the test (and hence the life cycle stage) and the P-gp
inhibitor. P-gp inhibitors have been shown to have diﬀerent modes of
action and levels of aﬃnity for diﬀerent ABC transporters. Ketoconazole
(K), an antifungal imidazole used in veterinary medicine, is a potent
inhibitor of cytochrome p450 in humans (Maurice et al., 1992) and has
been shown to alter the pharmacokinetics of several P-gp substrate
drugs by competitive inhibition at P-gp channels (Ward et al., 2004;
Kageyama et al., 2005; Hugnet et al., 2007; Bartley et al., 2009, 2012).
Additionally, it has been shown to compete with IVM at the cyathos-
tomin pgp-9 channel (Kaschny et al., 2015). Ivermectin aglycone (IVM-
AG) is an avermectin derivative that should act by competitive inhibi-
tion as predicted by in silico docking on the nematode Cel-P-gp1 (David
et al., 2016). Its activity is comparable with verapamil, one of the most
potent P-gp inhibitors, and it has greater aﬃnity for nematode versus
mammalian P-gp (Lespine et al., 2013). Pluronic 85 (P85) is a polax-
omer with a multimodal action, and is more commonly used as a na-
nocarrier in drug delivery systems; it incorporates into cell membranes
changing their microviscosity, which has the eﬀect of inhibiting ATPase
activity, thus reducing activity of ABC transporters (Batrakova and
Kabanov, 2008). They have been shown to be potent inhibitors of P-gps
and other ABC transporters such as MRP1 and MRP2 (Shaik et al.,
2008). Here, in the LMIT, IVM-AG and K increased the eﬀect of IVM on
L3 with a ‘resistant’ (Pop 1) phenotype, but had little eﬀect on L3 with a
sensitive phenotype (Pop 2). This suggests that P-gp activity is upre-
gulated in the resistant cyathostomin population, which corroborates
the ﬁnding of increased pgp-9 transcript in L3 from the same popula-
tion. A study by Demeler et al. (2013), tested diﬀerent P-gp inhibitors
against C. oncophora in the LDT and LMIT, and reported similar results.
In the current study, in the LMIT, P85 had a bi-modal eﬀect, whereby it
increased the eﬀect of IVM in both populations at low IVM con-
centrations, and at high IVM concentrations the eﬀect was reversed.
One study in C. elegans has also shown that the eﬀect of P-gp inhibitors
can be dependent on IVM concentration, although there was not a clear
reversal of the eﬀect as seen here (Ardelli and Prichard, 2013). On the
other hand, a study using P85 as a P-gp inhibitor with IVM in a larval
feeding assay in H. contortus and T. circumcincta, did not report a bi-
modal eﬀect (Bartley et al., 2009). One point to note is that much
higher concentrations are used in the LMIT than in assays on earlier
larval stages, and hence the eﬀect seen here may be an interaction
speciﬁc to these high concentrations.
In the LDT, K and P85 increased the eﬀect of IVM in both
cyathostomin populations. As mentioned above, the LDT did not dif-
ferentiate as well between the resistant and sensitive populations, and
therefore it follows logically that it also did not diﬀerentiate between
the eﬀects of P-gp inhibitors. Demeler et al. (2013) and Bartley et al.
(2009) also reported little diﬀerential eﬀect of P-gp inhibitors between
resistant and sensitive in the LDT and a larval feeding assay respec-
tively. So, although their eﬀect does not appear to be clearly linked
with IVM resistance status in the early larval stages of cyathostomins, P-
gp inhibitors markedly increase the eﬀect of IVM, which suggests that
these stages express P-gps which have the potential to extrude IVM. In
contrast to K and P85, it was found that IVM-AG did not have an eﬀect
in the LDT. This was most likely due to its use at a sub-optimal con-
centration for P-gp inhibition (during optimisation it was found that it
had an independent eﬀect at higher concentrations). Given its activity
in the LMIT, it is likely that it would have a synergistic eﬀect in the LDT
if used at a higher concentration, however it was not possible to test this
using our experimental set-up.
As observed here, there are reports of diﬀering eﬀects of P-gp in-
hibitors dependent on parasite population, test and P-gp inhibitor used.
For example, Raza et al. (2015) tested P-gp inhibitors, tariquidar, zo-
suquidar, elacridar, verapamil and valspodar, against H. contortus
larvae of diﬀering anthelmintic (IVM, levamisole, thiabendazole) sen-
sitivity, in the LDT and LMIT. They found that several compounds in-
creased sensitivity of both resistant and susceptible isolates, for ex-
ample, tariquidar with IVM in the LMIT and zosuquidar with IVM in the
LDT, whereas others had a signiﬁcant eﬀect on the resistant isolate
only. There is also evidence that there are diﬀerences between species
or isolates; for example, one study investigating the eﬀect of verapamil
on IVM in the LMIT showed there to be a positive eﬀect in resistant and
sensitive isolates from Ostertagia ostertagi, but only in a resistant isolate
of C. oncophora (AlGusbi et al., 2014). Our data supported by these
studies suggest that some inhibitors interact with P-gps representing
intrinsic pathways present across nematode populations with diﬀerent
drug sensitivities, and others interact with P-gps of signiﬁcance only to
resistant worms, and may represent an acquired resistance mechanism.
These interactions appear to alter depending on the test (and hence life
cycle stage) and nematode species/isolate.
Due to the evidence from in vitro studies, there is increasing interest
in the potential use of P-gp inhibitors to augment treatment eﬃcacy in
vivo. The proposed mechanisms of such combinations are: (i) reducing
eﬄux of drug from nematodes, and hence increasing the concentration
of drug at its target site within the nematode, and (ii) reducing excre-
tion of drugs by host animals, and hence increasing bioavailability.
Based on the results here, IVM-AG and ketoconazole are potential
candidates for taking forward to trials, as they both increased the eﬀect
Table 2
EC-50 values calculated for each population in the larval development test (LDT) and larval migration inhibition test (LMIT), with ivermectin (IVM) and IVM plus Pluronic 85 (P85)
(22 μM), ketoconazole (K) (10 μM) and ivermectin aglycone (IVM-AG) (8 and 60 nM for the LDT and LMIT, respectively). For each P-glycoprotein (P-gp) inhibitor a ratio of the EC-50
with IVM alone and the EC-50 with P-gp inhibitor is shown, deﬁned as the synergy ratio (SR).
Assay (LDT or LMIT) P-gp inhibitor EC-50 IVM alone, (95% conﬁdence interval) EC-50 IVM + p-gp inhibitor (95% conﬁdence interval) Synergy ratio
Population 1 LDT P85 9.81 (8.66–11.08) nM 1.63 (1.48–1.80 nM 6.0
K 8.17 (7.44–8.98) nM 3.20 (2.94–3.47) nM 3.6
IVM-AG 9.82 (8.69–11.08) nM 9.59 (8.18–11.21) nM 1.0
LMIT P85a 0.38 (0.23–0.72) μM (0.02 (0.02–0.03) μM) (19)
K 5.11 (4.30–6.06) μM 1.20 (1.04–1.40) μM 4.3
IVM-AG 13.70 (11.03–17.13) μM 3.79 (3.03–4.72) μM 3.6
Population 2 LDT P85 4.40 (4.07–4.75) nM 0.43 (0.38–0.48) nM 10.2
K 4.62 (4.23–5.04) nM 0.65 (0.60–0.71) nM 7.1
IVM-AG 4.40 (4.14–4.68) nM 3.40 (3.14–4.04) nM 1.3
LMIT P85a 0.14 (0.10–0.20) μM (0.02 (0.02–0.03) μM) (7)
K 0.86 (0.77–0.97) μM 1.08 (0.91–1.26) μM 0.8
IVM-AG 1.14 (0.95–1.36) μM 1.16 (0.97–1.38) μM 1.0
a As the baseline of the dose response curve diﬀered between IVM and IVM + P85 in the LMIT, the EC-50s cannot be compared with that of IVM alone, and hence the EC-50 and
synergy ratio are shown in brackets.
L.E. Peachey et al. IJP: Drugs and Drug Resistance 7 (2017) 388–398
395
of IVM in the ‘resistant’ population. To date, the results of trials in other
species have been equivocal. One study in sheep showed that, although
the plasma concentration of IVM was signiﬁcantly increased by co-ad-
ministration with K, there was no eﬀect on eﬃcacy against H. contortus
as measured by FECRT (Bartley et al., 2012). The same study showed a
moderate eﬀect of P85 on IVM eﬃcacy, even though the plasma con-
centration was similar to that seen with K, which might indicate that
P85 had a direct eﬀect on parasite P-gp function. The study that showed
the most convincing eﬀect of a P-gp, combined loperamide with IVM in
sheep against mixed GI nematode infection and led to a markedly im-
proved eﬃcacy (Lifschitz et al., 2010a). Loperamide has been shown to
increase plasma concentration of MLs (Lifschitz et al., 2002) and, ad-
ditionally it reduces faecal transit time and therefore may increase
exposure time of parasites to ML in the gut. Based on the data presented
here it would be logical to suggest an in vivo trial of Pgp-inhibitor-IVM
combination therapy in Equidae, and reassuringly some known P-gp
inhibitors have already been used systemically in Equidae, for example
K (Nappert et al., 1996), and loperamide (Sanchez, 2014), which may
facilitate future work. When considering in vivo trials it is important to
be aware of the potential side eﬀects of drug interactions, for example
increased toxicity of IVM due to increased bioavailability and plasma
levels, however, toxicity has not been noted in published in vivo trials
undertaken in other species.
5. Conclusion
The data presented implicate a role for P-gps in reduced sensitivity
to IVM in cyathostomins. The in vitro data conﬁrm that IVM interacts
with P-gps in cyathostomins. Speciﬁcally, K and IVM-AG increased the
eﬀect of IVM in the resistant cyathostomin isolate to a greater extent
than in the sensitive isolate, implicating interference with an acquired
resistance mechanism. These data support the possibility that P-gp in-
hibitors could be used in combination with IVM in vivo, as a novel
approach to improving the eﬃcacy of IVM in resistant cyathostomin
populations.
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